<SEC-DOCUMENT>0001737287-24-000055.txt : 20240807
<SEC-HEADER>0001737287-24-000055.hdr.sgml : 20240807
<ACCEPTANCE-DATETIME>20240807160423
ACCESSION NUMBER:		0001737287-24-000055
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240807
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240807
DATE AS OF CHANGE:		20240807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Allogene Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001737287
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				823562771
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38693
		FILM NUMBER:		241183522

	BUSINESS ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 457-2700

	MAIL ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>allo-20240807.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:27f93757-d9fa-418f-9f96-fcc213c6c904,g:3d81d4d6-d999-4de7-8b35-d76dffe7625b,d:22f529a80d7e4bd893e2014259b6664e-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>allo-20240807</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001737287</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="allo-20240807.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-07</xbrli:startDate><xbrli:endDate>2024-08-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i22f529a80d7e4bd893e2014259b6664e_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">____________________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">____________________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 7, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">_______________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Allogene Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">____________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:32.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38693</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">82-3562771</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">210 East Grand Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94080</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Address of principal executive offices including zip code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">457-2700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form 8-K):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:3.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">on&#160;which&#160;registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ALLO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b&#8211;2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b&#8211;2 of this chapter).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i22f529a80d7e4bd893e2014259b6664e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;7, 2024, Allogene Therapeutics, Inc. (the &#8220;Company&#8221;) provided a corporate update and announced its financial results for the quarter ended June&#160;30, 2024 in the press release attached hereto as Exhibit&#160;99.1, which is incorporated herein by reference.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item&#160;2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div><span><br/></span></div><div id="i22f529a80d7e4bd893e2014259b6664e_10"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.091%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="allo-20240630xexx991q224.htm">Press Release of the Company, dated August 7, 2024.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page of this report has been formatted in Inline XBRL.</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i22f529a80d7e4bd893e2014259b6664e_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.955%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALLOGENE THERAPEUTICS, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Chang, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Chang, M.D., Ph.D.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: August 7, 2024</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>allo-20240630xexx991q224.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ibd9e94cb7a0b4aef96db182b42747275_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:10pt"><img alt="g725933allogenea06a.jpg" src="g725933allogenea06a.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:176px"></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt">Cemacabtagene Ansegedleucel (Cema-Cel)&#58; 1L Consolidation in Large B-Cell Lymphoma (LBCL)</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Pivotal Phase 2 ALPHA3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trial Initiated in June 2024</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Patient Screening for Minimal Residual Disease (MRD) and Enrollment Proceeding as Planned with Ten Community and Academic Sites Opened to Date Across the US</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Enrollment Completion Expected in 1H 2026 and Potential BLA Submission in 2027</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">ALLO-329 in Autoimmune Disease (AID)</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Investigational New Drug (IND) Application for Next-Generation CD19&#47;CD70 Dual CAR with Dagger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Technology Designed for AID on Track for Q1 2025 with Proof-of-Concept Data Expected by YE 2025</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">ALLO-316 in Renal Cell Carcinoma (RCC)</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Phase 1 TRAVERSE Data Update Including Details on the Diagnostic and Treatment Algorithm Planned for YE 2024</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Ended Q2 2024 with $444.6 Million in Cash, Cash Equivalents and Investments&#59; Cash Runway Continues to be Projected into 2H 2026</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Conference Call and Webcast Scheduled for Today at 2&#58;00 PM PT&#47;5&#58;00 PM ET</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SOUTH SAN FRANCISCO, Calif.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, August 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, 2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene Therapeutics, Inc.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (Nasdaq&#58; ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T&#8482;) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended June 30, 2024.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;The second quarter has been an excellent example of the power of momentum, particularly as we bring into the fold community cancer centers who are eager to be a part of our pivotal Phase 2 ALPHA3 trial and we are now manufacturing all of our CAR T investigational products in-house,&#8221; said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. &#8220;Beyond the progress we&#8217;ve seen across our four core programs with cema-cel in blood cancers, ALLO-329 in autoimmune disease, and ALLO-316 in relapsed and refractory renal cell carcinoma, there is renewed energy from investigators, clinical trial sites, and top-tier investors as it becomes increasingly apparent that we have the potential to reshape the future of CAR T therapies.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Program Updates </font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cema-Cel&#58; Pivotal ALPHA3 1L Consolidation Trial in Large B Cell Lymphoma (LBCL)</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The pivotal Phase 2 ALPHA3 trial was initiated in June 2024 and site activation is ahead of schedule with ten community cancer and academic centers opened in less than two months. Patient screening for minimal residual disease (MRD) and enrollment are proceeding as planned. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This groundbreaking study is evaluating the use of cemacabtagene ansegedleucel (cema-cel) as part of the first line (1L) treatment regimen for patients with LBCL who are likely to relapse after standard 1L treatment. </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ALPHA3 is the first pivotal trial to offer CAR T as part of 1L treatment consolidation.  </font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This innovative ALPHA3 trial will identify patients at high risk for re</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">lapse after 1L treatment by utilizing the Foresight CLARITY&#8482; Investigational Use Only (IUO) MRD test, powered by PhasED-Seq&#8482;. </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This randomized trial will enroll approximately 240 patients and is designed to demonstrate a meaningful improvement in event free survival (EFS) in patients treated with cema-cel relative to patients who receive the current standard of care (observation). ALPHA3 is expected to complete enrollment in 1H 2026. Efficacy analyses are expected to occur in 2026 and will include an interim EFS analysis monitored by the independent Data Safety Monitoring Board (DSMB) in 1H 2026 and the data readout of the primary EFS analysis YE 2026. A potential biologics license application (BLA) submission is targeted for 2027.</font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cema-Cel&#58; Phase 1 Trial in Chronic Lymphocytic Leukemia (CLL)</font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Enrollment is ongoing in the relapsed&#47;refractory (r&#47;r) CLL cohort of the Phase 1 ALPHA2 trial of cema-cel. Initial data readout from the CLL cohort is projected by early 2025.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ALLO-329&#58; CD19&#47;CD70 Dual CAR with Dagger</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> Technology in Autoimmune Disease (AID)</font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ALLO-329, the Company&#8217;s first CRISPR-based AlloCAR T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8482;</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> investigational product for AID, incorporates the Dagger</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> technology, which is intended to reduce or eliminate the need for lymphodepletion while targeting CD19+ B-cells and CD70+ </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">activated T-cells, both of which are likely to play a role in AID. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company plans to file an investigational new drug (IND) application in Q1 2025 and expects to have proof-of-concept by YE 2025.</font></div><div><font><br></font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ALLO-316&#58; TRAVERSE Trial in Renal Cell Carcinoma (RCC)</font></div><div><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A Phase 1 data update from approximately 20 patients with CD70 positive RCC, which will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients, is planned by YE 2024. In April 2024, the Company announced a $15 million award from the California Institute for Regenerative Medicine (CIRM) to support the ongoing TRAVERSE trial with ALLO-316 in RCC.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2024 Second Quarter Financial Results</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were $50.4 million for the second quarter of 2024, which includes $5.3 million of non-cash stock-based compensation expense.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were $16.1 million for the second quarter of 2024, which includes $8.2 million of non-cash stock-based compensation expense.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss for the second quarter of 2024 was $66.4 million, or $0.35 per share, including non-cash stock-based compensation expense of $13.6 million and $5.0 million in non-cash impairment of long-lived asset expense.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company had $444.6 million in cash, cash equivalents, and investments as of June 30, 2024.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the cash runway as of June 30, 2024, the Company continues to expect its cash runway to fund operations into the second half of 2026. Guidance remains unchanged from the most recent update with an expectation of a decrease in cash, cash equivalents, and investments of approximately $200 million in 2024. GAAP Operating Expenses are expected to be approximately $300 million, including estimated non-cash stock-based compensation expense of approximately $60 million. These estimates exclude any impact from potential business development activities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call and Webcast Details</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene will host a live conference call and webcast today at 2&#58;00 PM PT&#47;5&#58;00 PM ET to discuss financial results and provide a business update. If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call, which will identify you as the participant and allow you the option to ask a question. The listen-only webcast will be made available on the Company's website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">www.allogene.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About Allogene Therapeutics</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T&#8482;) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of &#8220;off-the-shelf&#8221; CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">www.allogene.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and follow Allogene Therapeutics on X (formerly Twitter) and LinkedIn.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cautionary Note on Forward-Looking Statements </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as &#8220;proceeding as planned,&#8221; &#8220;on track,&#8221; &#8220;ahead,&#8221; &#8220;targeted,&#8221; &#8220;ongoing,&#8221; &#8220;likely to,&#8221; &#8220;believes,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;estimates,&#8221;  &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;designed to, &#8220; &#8220;can, &#8220;, &#8220;become,&#8221;  &#8220;may,&#8221; &#8220;could,&#8221;  &#8220;will,&#8221; &#8220;should&#8221; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things&#58; Allogene's belief that it has the potential to reshape the future of CAR T therapies&#59; the potential market opportunity for Allogene&#8217;s  product candidates&#59; ALPHA3 being a pivotal trial&#59; the design of ALPHA3&#59; the potential of ALPHA3 to be administered as part of 1L treatment consolidation&#59; the potential for cema-cel to become the part of the first line treatment regimen available to patients with LBCL who are likely to relapse after standard 1L treatment&#59;  plans to administer cema-cel in community cancer centers in the ALPHA3 trial&#59; the potential outcomes of ALPHA3&#59; the pace, timing and extent to which we may initiate or enroll patients in our clinical trials or release data from such trials, including ALPHA2, ALPHA3, ALLO-329, and TRAVERSE trials&#59; clinical outcomes, which may materially change as more patient data become available&#59; the design and potential benefits of our Dagger&#174; technology, including the ability to reduce or eliminate the need for lymphodepletion, and the expected benefits therefrom, to treat autoimmune disease, and our plans to deploy the Dagger&#174; technology&#59; the potential for our product candidates to be approved&#59; the potential benefits of AlloCAR TTM products&#59; the ability of our product candidates to treat various stages and types of cancers including hematological and solid tumors or to treat autoimmune disease&#59; the potential ability of our diagnostic and treatment algorithm to address emerging safety findings or mitigate treatment-associated hyperinflammatory response without compromising CAR T function&#59; our expectation that our cash runway extends into 2026&#59; financial guidance for 2024&#59; the modes of action or the biologic impacts of our product candidates&#59; and other statements related </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to future events or conditions. Various factors may cause material differences between Allogene&#8217;s expectations and actual results, including, risks and uncertainties related to&#58; changes in the macroeconomic environment or industry that impact our business&#59; competition&#59; risks related to third-party performance&#59; our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval&#59; the limited nature of the Phase 1 data from our clinical trials and the extent to which such data may or may not be validated in any future clinical trial&#59; preliminary results may not be indicative of results that may be observed in the future&#59; our ability to maintain intellectual property rights necessary for the continued development of our product candidates, including pursuant to our license agreements&#59; our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval or limit their commercial potential&#59; the extent to which the Food and Drug Administration disagrees with our clinical or regulatory plans or the import of our clinical results, which could cause future delays to our clinical trials or require additional clinical trials&#59; we may encounter difficulties enrolling patients in our clinical trials, including ALPHA2, ALPHA3, ALLO-329 and TRAVERSE trials&#59; there is no guarantee that Foresight will successfully develop an MRD assay for use as a companion diagnostic with cema-cel, and without a companion diagnostic the prospects for cema-cel could be materially and negatively impacted&#59; we may not be able to demonstrate the safety and efficacy of our product candidates in our clinical trials, which could prevent or delay regulatory approval and commercialization&#59; challenges with manufacturing or optimizing manufacturing of our product candidates, including manufacturing our CAR T product candidates in-house, or any companion diagnostic for use with our product candidates&#59; and our ability to obtain additional financing to develop our product candidates and implement our operating plans. These and other risks are discussed in greater detail in Allogene&#8217;s filings with the Securities and Exchange Commission (SEC), including without limitation under the &#8220;Risk Factors&#8221; heading in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, being filed with the SEC today. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Caution should be exercised regarding statements comparing autologous CAR T data. There are differences in the clinical trial design, patient populations, published data, follow-up times and the product candidates themselves, and the results from the clinical trials of autologous products may have no interpretative value on our existing or future results.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AlloCAR T&#8482; and Dagger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> are trademarks of Allogene Therapeutics, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CLARITY&#8482; and PhasED-Seq&#8482; are trademarks of Foresight Diagnostics.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene&#8217;s investigational AlloCAR T&#8482; oncology products utilize Cellectis technologies. The anti-CD19 oncology products are developed based on an exclusive license granted by Cellectis to Servier. Servier, which has an exclusive license to the anti-CD19 AlloCAR T&#8482; investigational products from Cellectis, has granted Allogene exclusive rights to these products in the U.S., all EU Member States and the United Kingdom. The anti-CD70 AlloCAR T program is licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to this AlloCAR T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> program. ALLO-329 (CD19&#47;CD70) in autoimmune disease uses CRISPR gene-editing technology.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ibd9e94cb7a0b4aef96db182b42747275_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALLOGENE THERAPEUTICS, INC.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED FINANCIAL DATA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited&#59; in thousands, except share and per share data)</font></div><div id="ibd9e94cb7a0b4aef96db182b42747275_7"></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF OPERATIONS</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue - related party</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,355&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,038&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,087&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,524&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,989&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,431&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,562&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,431)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,540)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,988&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income and expense, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,470)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,073&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,358)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,232)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.54)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares used in computing net loss per share, basic and diluted</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,026,638&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,795,826&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div id="ibd9e94cb7a0b4aef96db182b42747275_10"></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED BALANCE SHEET DATA</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and investments</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,628&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,697&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,883&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642,837&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,845&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,604&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515,038&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512,233&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allogene Media&#47;Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christine Cassiano</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EVP, Chief Corporate Affairs &#38; Brand Strategy Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Christine.Cassiano&#64;allogene.com</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>allo-20240807.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:27f93757-d9fa-418f-9f96-fcc213c6c904,g:3d81d4d6-d999-4de7-8b35-d76dffe7625b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:allo="http://allogene.com/20240807" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://allogene.com/20240807">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20240807_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20240807_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://allogene.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>allo-20240807_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:27f93757-d9fa-418f-9f96-fcc213c6c904,g:3d81d4d6-d999-4de7-8b35-d76dffe7625b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ca83fd7d-da02-492d-8fe1-b3db6f6e4931_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1093bd3e-4d70-467c-800d-5bf872805b7d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c998b359-a214-4d94-8a0c-1f24a9c49286_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c4ce68ac-3b21-47f9-a10b-3d030b75957d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_fa071ad3-ae5b-4a0c-b77e-7e9d4e4dbf70_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_f66ba9c6-54f1-4b6c-8031-b6bdd9738b2d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_85556f3e-9c6e-4f95-a4e4-76cb74761bfd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_324a3ffe-e72b-46d6-b0ca-465e879432f0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_d19cf3fa-375c-4b6d-9444-fa473ca569fb_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1df591f1-6987-4c51-b049-bef3ee016114_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_453edba7-be45-4473-8364-bbccb9b564d8_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_aa7e8f4f-17d0-4c15-b010-7ad06f46b42f_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_fc897833-6d5f-4207-98e0-c38c8fb5ac33_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_de2e62bd-70b8-42bf-9f69-449ada3ec485_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d8cc70c4-b9f8-4e9f-94e8-d37d89754264_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9931c414-1daa-4d06-a258-3685c04495d9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_21a2bff5-58ff-4615-ba84-2cb45303caed_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b3fe7224-5ac8-497a-9e1e-7218b16fa34c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_235f0177-f16c-4fc8-b76f-38cb34f7598d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b743ae8b-cc24-4309-9f55-b307863a481c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_cb25c492-323d-4d0e-84cb-92f3fbedf5f7_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0ebd110a-7388-4ac1-a75e-35b735e804bb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d5f7189a-002c-420f-90a3-7a1e5a782387_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>allo-20240807_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:27f93757-d9fa-418f-9f96-fcc213c6c904,g:3d81d4d6-d999-4de7-8b35-d76dffe7625b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://allogene.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="allo-20240807.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://allogene.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b7fccce4-1842-4436-bb13-4ca3f5f4a4a0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_DocumentType_b7fccce4-1842-4436-bb13-4ca3f5f4a4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1a550c33-ffe1-4976-83d4-baed7e78fb73" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_DocumentPeriodEndDate_1a550c33-ffe1-4976-83d4-baed7e78fb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_41bcb974-2cfb-44d0-8154-a8358b130fa7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_EntityRegistrantName_41bcb974-2cfb-44d0-8154-a8358b130fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_dad4f6a3-fd73-4b1a-99f0-dc0fa7b5babe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_EntityCentralIndexKey_dad4f6a3-fd73-4b1a-99f0-dc0fa7b5babe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_07611215-ec41-4d61-8ae1-1bd5c8194bf3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_AmendmentFlag_07611215-ec41-4d61-8ae1-1bd5c8194bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f5f65bf2-8d1b-4519-b415-ff2d609d51a8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f5f65bf2-8d1b-4519-b415-ff2d609d51a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_abf5145a-4c0b-4d79-9c7f-fe592210b63f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_EntityFileNumber_abf5145a-4c0b-4d79-9c7f-fe592210b63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_28c90bf0-6cdb-47c0-a053-a2bb5e11d910" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_EntityTaxIdentificationNumber_28c90bf0-6cdb-47c0-a053-a2bb5e11d910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8c080b13-e832-44d9-9b60-8ca00075b35b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_EntityAddressAddressLine1_8c080b13-e832-44d9-9b60-8ca00075b35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3a481be5-f58d-433e-aac2-498c3cc7a524" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_EntityAddressCityOrTown_3a481be5-f58d-433e-aac2-498c3cc7a524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_48789150-11f2-4eab-bcd7-ffb13bbfe9bb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_EntityAddressStateOrProvince_48789150-11f2-4eab-bcd7-ffb13bbfe9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_41c06f47-9953-4f31-b19b-3480693f00e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_EntityAddressPostalZipCode_41c06f47-9953-4f31-b19b-3480693f00e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6d9f7c91-500d-483d-96a2-612ef0cbe18a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_CityAreaCode_6d9f7c91-500d-483d-96a2-612ef0cbe18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_23b99dd7-4ff0-42f9-9d09-39bc3fbd21d3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_LocalPhoneNumber_23b99dd7-4ff0-42f9-9d09-39bc3fbd21d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_88d360df-5cfd-4f0c-b2e2-dce3226be1db" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_WrittenCommunications_88d360df-5cfd-4f0c-b2e2-dce3226be1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_550338aa-3075-4aa7-b3fa-288f077ee053" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_SolicitingMaterial_550338aa-3075-4aa7-b3fa-288f077ee053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_99b8d607-462c-4f26-9687-401be2da2a71" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_PreCommencementTenderOffer_99b8d607-462c-4f26-9687-401be2da2a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_21f9170a-96b8-4859-bbe4-ffa1840ad960" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_21f9170a-96b8-4859-bbe4-ffa1840ad960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8c00ce02-8ad7-409c-adca-644e57388515" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_Security12bTitle_8c00ce02-8ad7-409c-adca-644e57388515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_79f95b81-add0-4bd3-889d-2432b6dfc3f5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_TradingSymbol_79f95b81-add0-4bd3-889d-2432b6dfc3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2c25e96b-01c9-4e05-ab73-e892235f9b81" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_SecurityExchangeName_2c25e96b-01c9-4e05-ab73-e892235f9b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_49b0383f-f755-4d7e-9918-854232bd29f2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4dadc040-8463-4630-9402-8db6aaedcab6" xlink:to="loc_dei_EntityEmergingGrowthCompany_49b0383f-f755-4d7e-9918-854232bd29f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g725933allogenea06a.jpg
<TEXT>
begin 644 g725933allogenea06a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  P ,P# 2(  A$! Q$!_\0
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M[Z7_ .AWU0_\%+#_ ,;^OV>?^O;0O_3A?5)^WC,L/_!Q/\"6;[OD:2OXF2^
M_G6U/['_ %[9PXQ_O,1_V%4_RB4_^"H!US_@H7_P5E\"_LTMJEWH_@?P^(;W
M4!:N"TTKVYNKBX*GY3(D 6&(L&\LO(P!W$5]H>*O^"-O[./B;X3R>$5^&>BZ
M7;^08H=3L%,>K6[8P)1='=(S@\_O"RD]5()%?'G_  5N\#^,/V%/^"B'@O\
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MPA^%\]QI%E8QB=EG,.P/$HB#,K7$^6DD7#-'"B[AM3'M/A^5HO\ @YYO]O\
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@]/Q^XYL3_9<:3A@:/LVY75E9*-MG[SN[];*^NU[+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140588522251568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Aug. 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  07,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Allogene Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001737287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3562771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">210 East Grand Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">457-2700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALLO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M/UY_ 5!+ 0(4 Q0    ( (N !UD'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ BX '64@&WZ'N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ BX '69E<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " "+@ =9@B>L:FL$  #2$   &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ BX '69^@&_"Q @  X@P   T              ( !K@P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " "+@ =9EXJ[',     3 @  "P
M    @ &*#P  7W)E;',O+G)E;'-02P$"% ,4    " "+@ =9'#AEZC\!   \
M @  #P              @ %S$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ BX '620>FZ*M    ^ $  !H              ( !WQ$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ BX '6660>9(9 0  SP,
M !,              ( !Q!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  #A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="allo-20240807.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="allo-20240807.htm">allo-20240807.htm</File>
    <File>allo-20240807.xsd</File>
    <File>allo-20240807_lab.xml</File>
    <File>allo-20240807_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "allo-20240807.htm": {
   "nsprefix": "allo",
   "nsuri": "http://allogene.com/20240807",
   "dts": {
    "inline": {
     "local": [
      "allo-20240807.htm"
     ]
    },
    "schema": {
     "local": [
      "allo-20240807.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "allo-20240807_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "allo-20240807_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://allogene.com/role/DocumentandEntityInformationDocument",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "shortName": "Document and Entity Information Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "allo-20240807.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "allo-20240807.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001737287-24-000055-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001737287-24-000055-xbrl.zip
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M^D53R;ZT"0^3;Z>&Y#NUI"\:E8"3;<BE@5%LLKAMP7Z ^:T .2"9:N1]W)X
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MIXB<4D*WS'BMJB.+"T&F.B(XHXN64'U#HX."G^=-"\0C'>?3JU**Q1'WLXE
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M;V^W'C;F);+L&\G5O0.G5J^M&5=_A-QZ]KJZPCOG>C(VYX]Z/NXH]AYA]^M
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MW$W&;=,P_J<DNW;.XHB"3(P$,DU]5O.LST;%'4R8A%&[%B4P/*$CG^6MHU
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M\]\9_XKRZRU4^+_9F]+;K[ OL>31-?@H5.+5%LRG6/*S=C%^@8$$W5@,H2,
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M<[/#U=W<]]8["#9OQJCU!U!+ P04    " "+@ =9K]0=*BT*  !]50  %0
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MP!.#N=_>+J0'QKL#^T6)V]($?G<OKLV;K#ZRI9IK%A+() ),Q1S@>HGCA"A
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M?C?.S:/3%]MGLO7_UGGZXG]02P,$%     @ BX '6?).DRZZ!@  ,S$  !4
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M1KGQ6>/]P)A\O7&XL*/Q\6KQ1,H+.'!R\'"B?6N?L3\Y^!=02P$"% ,4
M" "+@ =9U]C[:(\>  #YT0  '               @ $     86QL;RTR,#(T
M,#8S,'AE>'@Y.3%Q,C(T+FAT;5!+ 0(4 Q0    ( (N !UD;W;)^1P\  *ME
M   1              "  <D>  !A;&QO+3(P,C0P.# W+FAT;5!+ 0(4 Q0
M   ( (N !UE10>]<@ (  ,4'   1              "  3\N  !A;&QO+3(P
M,C0P.# W+GAS9%!+ 0(4 Q0    ( (N !UFOU!TJ+0H  'U5   5
M      "  >XP  !A;&QO+3(P,C0P.# W7VQA8BYX;6Q02P$"% ,4    " "+
M@ =9\DZ3+KH&   S,0  %0              @ %..P  86QL;RTR,#(T,#@P
?-U]P<F4N>&UL4$L%!@     %  4 3@$  #M"      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>allo-20240807_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="allo-20240807.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2024-08-07</startDate>
            <endDate>2024-08-07</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001737287</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-08-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Allogene Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38693</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">82-3562771</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">210 East Grand Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">457-2700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ALLO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
